OneMedNet Corp ONMDW
is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data ("iRWDTM"). OneMedNet's
innovative solutions connect healthcare providers and patients satisfying a crucial need within the life sciences field offering direct
access to clinical images and the associated contextual patient record. OneMedNet's innovative technology proved the commercial
and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | $643.0K | $1.0M | $1.2M | — | — |
| Cost of revenue | $1.9M | $924.0K | $1.1M | $1.5M | — | — |
| Gross profit | -$503.0K | -$281.0K | -$129.0K | -$360.0K | — | — |
| R&D | $1.5M | $1.5M | $2.1M | $1.6M | — | — |
| SG&A | $6.4M | $7.0M | $3.5M | $4.8M | — | — |
| Total operating expenses | $9.2M | $9.3M | $6.7M | $7.4M | — | — |
| Operating income | -$9.7M | -$9.6M | -$6.9M | -$7.7M | — | — |
| Interest expense | $67.0K | $147.0K | $11.0K | $403.3K | — | — |
| Pre-tax income | -$2.8M | -$10.1M | -$33.8M | -$30.4M | — | — |
| Income tax | $1.0K | $2.0K | $18.0K | $17.0K | — | — |
| Net income | -$2.8M | -$10.1M | -$33.8M | -$30.5M | — | — |
| EPS, basic | -0.06 | -0.36 | -4.65 | -7.66 | — | — |
| EPS, diluted | -0.06 | -0.36 | -4.65 | -7.66 | — | — |
| Shares, diluted (wtd. avg.) | $44.5M | $28.1M | $7.3M | $4.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $585.0K | $172.0K | $47.0K | $271.0K | $453.2K | $0 |
| Receivables | $495.0K | $213.0K | $152.0K | $19.0K | — | — |
| Total current assets | $2.1M | $3.6M | $365.0K | $391.0K | $536.2K | — |
| Property, plant and equipment | $56.0K | $108.0K | $99.0K | $83.0K | — | — |
| Total assets | $2.2M | $3.7M | $464.0K | $1.3M | $117.9M | — |
| Accounts payable | $3.5M | $6.0M | $4.7M | $1.2M | — | — |
| Short-term debt | $974.0K | $9.4M | $465.0K | — | — | — |
| Total current liabilities | $4.8M | $19.2M | $13.8M | $26.1M | $290.0K | — |
| Long-term debt | $220.0K | $2.3M | $465.0K | — | — | — |
| Total liabilities | $5.1M | $19.7M | $13.9M | $27.6M | $9.2M | — |
| Retained earnings | -$104.4M | -$101.6M | -$91.4M | -$57.7M | -$8.6M | — |
| Total equity | -$3.0M | -$15.9M | -$13.4M | -$26.4M | -$7.1M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.5M | -$7.0M | -$4.8M | -$4.7M | — | — |
| Depreciation and amortisation | $65.0K | $57.0K | $28.0K | $25.0K | — | — |
| Stock-based compensation | $2.0M | $628.0K | $1.5M | $1.9M | — | — |
| Capital expenditure | $13.0K | $51.0K | $44.0K | $58.0K | — | — |
| Investing cash flow | $2.3M | -$2.0M | -$44.0K | -$58.0K | — | — |
| Financing cash flow | $5.6M | $9.1M | $4.6M | $4.3M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-032512.
Others in SIC 8731
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $44.69B | 34.2x | 5.9% |
| INCY | INCYTE CORP | $25.32B | 19.8x | 21.2% |
| MEDP | Medpace Holdings, Inc. | $16.50B | 38.7x | 20.0% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $13.77B | — | -0.9% |
| ABSI | Absci Corp | $1.51B | — | -38.2% |
| OABI | OmniAb, Inc. | $629.5M | — | -29.3% |
| NRC | NRC HEALTH | $476.2M | 0.4x | -4.0% |
| MXCT | MAXCYTE, INC. | $132.1M | — | -5.7% |